Your session is about to expire
← Back to Search
Ixazomib + Cyclophosphamide + Dexamethasone for Multiple Myeloma
Study Summary
This trial will test if ixazomib is more effective and has less side effects than bortezomib.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 4 trial • 45 Patients • NCT03416374Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't taken specific strong medications or herbal supplements like Ginkgo biloba or St. John's wort in the last 14 days.I have untreated Multiple Myeloma, but may have had emergency steroids or radiation.I have not had radiotherapy in the last 14 days.I do not have an active infection, hepatitis B or C, or HIV.I do not have any stomach or intestine problems that affect my ability to swallow pills.I am 18 years old or older.I haven't had any cancer besides nonmelanoma skin cancer or carcinoma in situ, or if I have, it was treated over 2 years ago with no remaining signs.I have moderate to severe nerve damage or mild with pain.My multiple myeloma diagnosis is confirmed by a pathology report.My kidneys are functioning well enough for treatment.I am a woman who is either not able to have children, practices safe contraception, or is not sexually active.I am a male and agree to use effective contraception or practice true abstinence during and up to 90 days after the study.My tests show measurable signs of my disease, as defined by specific criteria.I am not pregnant or breastfeeding.My blood tests show enough neutrophils and platelets without recent transfusions.I am fully active or can carry out light work.My myeloma has spread to my brain or spinal cord.My liver tests are within normal limits.I have not had any surgery in the last 14 days.I do not have any uncontrolled heart problems.I have not had a serious infection or needed antibiotics in the last week.You are expected to live for at least 6 more months, as confirmed by your doctor.
- Group 1: Ixazomib Regimen
- Approved for 60 Other Conditions - This treatment demonstrated efficacy for 60 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are participants being enrolled in this clinical trial at the current time?
"This study is no longer recruiting patients. Although it was last updated on 7/21/2022, the trial was originally posted on 8/1/2015. There are presently 827 trials actively enrolling patients with multiple myeloma and 1349 trials for Ixazomib actively enrolling participants if you are seeking other studies to participate in."
What conditions does Ixazomib typically help ameliorate?
"Ixazomib is used to treat synovitis, but it has also been found helpful in managing ophthalmia, sympathetic nerve disorders, and various types of cancer including those effecting the lungs and retina."
Are there any other scientific papers that mention Ixazomib?
"There are 1349 clinical trials currently underway for the use of Ixazomib. 278 of these studies have reached Phase 3 testing. The majority of these trials originate from Philadelphia, Pennsylvania; however, there are 42384 total locations running similar tests."
Could you please give an overview of Ixazomib's safety profile?
"While there is some data suggesting Ixazomib's safety, it is still in Phase 2 of clinical trials and has not been proven effective yet. Consequently, our team at Power only rates its safety as a 2."
How many patients are included in the scope of this experiment?
"Though this particular clinical trial is not seeking new participants at the moment, there are plenty of other research studies that might be a better fit. There are 827 trials actively recruiting patients with multiple myeloma and 1349 Ixazomib trials enrolling patients right now."
Share this study with friends
Copy Link
Messenger